Maravai LifeSciences Reports 40.5% Revenue Growth to $65.8 Million in Q1 2026

Maravai LifeSciences Holdings, Inc. reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $65.8 million, a 40.5% increase from $46.9 million in the same period last year. The TriLink segment, which focuses on nucleic acid products, contributed $47.5 million, up 65.1% from $28.8 million, largely driven by $14.3 million in high-volume orders for CleanCap® products related to COVID-19 vaccine programs. The Cygnus segment saw a modest increase in revenue to $18.4 million, up 1.4% from $18.1 million, attributed to strong demand in North America and Europe, although impacted by lower orders from China.

The company's gross profit surged to $33.7 million, compared to $7.7 million in the prior year, resulting in a gross profit margin of 51.2%, a substantial increase from 16.5%. This improvement was primarily due to a decrease in cost of revenue, which fell by 17.9% to $32.1 million, driven by reductions in personnel expenses and other operational costs as part of the 2025 Corporate Realignment Plan. Operating expenses also decreased significantly, totaling $35.9 million, down 37% from $56.9 million, reflecting lower selling, general, and administrative costs.

Despite the positive revenue growth, Maravai reported a net loss of $6.4 million for the quarter, a substantial improvement from a net loss of $52.9 million in the same period last year. The loss attributable to Maravai LifeSciences Holdings, Inc. was $3.7 million, compared to $29.9 million in the prior year. The company’s adjusted EBITDA for the quarter was $20.3 million, a notable recovery from a negative $10.5 million in the previous year, indicating a turnaround in operational efficiency.

In terms of strategic developments, Maravai has been focusing on expanding its customer base and enhancing its product offerings. The company employed 416 full-time employees as of March 31, 2026, and continues to invest in research and development to meet customer demands. The company also executed a voluntary prepayment of $50 million on its term loan in February 2026, reducing its long-term debt to $241.0 million as of the end of the quarter.

Looking ahead, Maravai anticipates that the first quarter of 2026 will be the highest revenue quarter of the year, as it does not expect further high-volume CleanCap orders for COVID-19 vaccine programs for the remainder of 2026. The company remains committed to its strategic initiatives and aims to leverage its existing cash reserves and credit facilities to support ongoing operations and growth opportunities.